ClinicalTrials.gg
Status unknownNCT02752867Updated Feb 26, 2019

An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction

An interventional study of Jianpi Yishen Huatan Granules and the placebo in Cognitive Impairment, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
168th of 191
40 · median 110
Started
2016
with 8 others
No phase
139 of 310
61 open now
Registered
29th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 168th largest by planned enrollment of the 191 interventional ones that give a count, is one of 9 that started in 2016, is one of 139 with no phase, and was the 29th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to explore the pathogenesis of cognitive impairment after acute cerebral infarction by applying the multimodal function MRI to dynamically observe the changes of the value of NAA,Cho,Cr,FA in a certain region in the brain and the function of the brain ,and to provide a visual instrument for evaluating the therapeutical effects of Chinese medicine through the application of multimodal function MRI to observe the changes of the neurotransmitter in certain area in the brain before and after the treatment.

Read the detailed description

The present study is designed to assess the efficacy and safety of Jianpi Yishen Huatan granules with cognitive impairment after Acute Cerebral Infarction by fMRI and neuropsychology scales,as well as observe the symptoms,syndrome characteristics and neuropsychological changes of patients with cognitive dysfunction after acute cerebral infarction.And explore the pathogenesis of cognitive impairment after acute cerebral infarction by applying the multimodal function MRI to dynamically observe the changes of the value of NAA,Cho,Cr,FA in a certain region in the brain and the function of the brain ,and to provide a visual instrument for evaluating the therapeutical effects of Chinese medicine through the application of multimodal function MRI to observe the changes of the neurotransmitter in certain area in the brain before and after the treatment.

The sample size is 40 of which 20 are from the intervention group and 20 are from the control group.

03

Conditions studied

  • Cognitive Impairment

Keywords

  • traditional Chinese medicine granules
  • Cognitive Impairment
  • Acute cerebral infraction
  • treatment
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients conform to the diagnostic criteria of acute ischemic stroke.
  • The cerebral infarction area lies in the blood supply area of middle cerebral artery: basal ganglia,corona radiate region or other subcortical regions..
  • The cumulative infarction area is no more than 3.0 cm.
  • Stroke onset within 21 days
  • Age from forty to eighty, gender not limited
  • Neuropsychological assessments: Scale scores less than 26 points or MMSE scores range from 19 points to 26 points in literates or MMSE scores range from 17 points to 24 points in illiterates
  • Informed and signed the

Exclusion criteria

Exclusion Criteria:

  • Stroke patients with the causes of cerebral hemorrhage, subarachnoid hemorrhage, brain tumors, brain injury, or blood diseases and so on.
  • Stroke with an onset of more than 21 days
  • Cerebral embolism caused by atrial fibrillation resulted from rheumatic heart disease, coronary heart disease and other heart diseases.
  • Patients who cannot cooperate with the check due to serious visual, hearing dysfunction, apraxia, aphasia.
  • Patients with other neurological diseases which can affect cognitive function (for example:Alzheimer's Disease,Parkinson's disease, frontotemporal dementia,Huntington's disease)
  • Patients with communication difficulties, or psychiatric disease
  • Depression (Hamilton Depression Scale scores more than or equal to 17 points)
  • Diagnosed with alcohol or drug dependence within the past six months
  • With other diseases which can cause cognitive dysfunction, Such as trauma,tumor or infection of the central nervous system, metabolic disorders, normal pressure hydrocephalus , folic acid or vitamin B12 Deficiency, thyroid hypofunction,sever anemia,sever Parkinson's Disease, encephalitis, syphilis or
  • With a previous history of stroke and serious sequelae, and cannot cope with neuropsychological examination
  • With severe primary diseases, and cannot comply with the above scheme
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Jianpi Yishen Huatan Granules group

    Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.

    Drug: Jianpi Yishen Huatan Granules

  • Placebo comparator
    The control group

    Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.

    Other: the placebo

Interventions

  • DrugJianpi Yishen Huatan Granules

    Jianpi Yishen Huatan Granules contain Herba cistanche,Fructus Alpinia Oxyphyllae,Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one

    Also known as: Jianpi Yishen Huatan Granules group

  • Otherthe placebo

    Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one

    Also known as: the placebo group

06

What researchers measure

Primary outcomes

  1. Changes of the fMRI outcome after the treatment

    Using the fMRI to measure the changes of neurotransmitter and brain function in the brain before and after the treatment.

    Time frame: 90 days

  2. Mini-mental state examination(MMSE)

    MMSE is an acknowledged scale to measure cognition function from the aspects of orientation ability, memory, attention, calculation ability, recall and language,etc.

    Time frame: 90 days

  3. Montreal Cognitive Assessment scale(MoCA)

    Using this scale to measure cognitive function

    Time frame: 90 days

  4. Stroop Color- Word Association Test(Stroop test)

    This is a test used to find out the memory and executive function of patients.The test contains three small test.

    Time frame: 90 days

  5. Numerical sequence test(DS-S)

    Using Numerical sequence test(DS-S) to examine memory

    Time frame: 90 days

  6. Digital color connection test (CCT)

    Using Digital color connection test (CCT) to examine executive function and attention

    Time frame: 90 days

  7. Verbal memory test(HVLT)

    Using Verbal memory test(HVLT) to examine verbal memory

    Time frame: 90 days

  8. Clinical Dementia Rating scale(CDR)

    Using Clinical Dementia Rating scale(CDR) to measure the severity of dementia

    Time frame: 90 days

Secondary outcomes

  1. National institute of health stroke scale

    Using National institute of health stroke scale to measure the severity of stroke

    Time frame: 90 days

  2. Modified Rankin scale

    Using Modified Rankin scale to measure the recovery of neurological function

    Time frame: 90 days

  3. Activity of Daily Living Scale

    Using this scale to measure daily living ability

    Time frame: 90 days

  4. Scores of Chinese medicine symptoms

    Scores of Chinese medicine symptoms, which is a scale resulted from literature research, the argumentation of experts and clinical observation,contain 23 items of the core symptoms of cognitive impairment. And the scale is used to measure the changes of symptoms of Chinese medicine before and after treatment.

    Time frame: 90 days

Other outcomes

  1. whole blood cell test

    blood routine test

    Time frame: 90 days

  2. routine urine test

    routine urine test

    Time frame: 90 days

  3. Liver function

    test the blood to detect the liver function,such as alanine aminotransferase(ALT) ,aspartate aminotransferase(AST),total bilirubin (TBIL), γ-glutamyl transferase(γ-GT).

    Time frame: 90 days

  4. electrocardiogram

    electrocardiograms are given before the experiment and on the 90th day of the experiment to test the condition of the patients' heart.

    Time frame: 90 days

  5. homocysteine

    detect the homocysteine in the blood

    Time frame: 90 days

  6. routine stool test

    examine stool of the patients

    Time frame: 90 days

  7. kidney function

    test the blood to detect the kidney function,such as blood urea nitrogen(BUN),creatinine (CRE),Uric acid(UA)

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology,Dongfang Hospital,Beijing University of Chinese Medicine
    Beijing, Beijing 100078, China
    Recruiting
    • Yunling Zhang, PhD,MD · Contact86 10 67689634
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Aug 2019 and a completion of Nov 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2016
First posted
Apr 27, 2016
Start
Dec 2016
Primary completionEst.
Aug 2019
CompletionEst.
Nov 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02752867
Lead sponsor
Dongfang Hospital Beijing University of Chinese Medicine
Responsible party
Yunling Zhang (President of Dongfang Hospital, Dongfang Hospital Beijing University of Chinese Medicine) — Principal investigator
First posted
Apr 27, 2016
Start date
Dec 2016
Primary completion
Aug 2019 (estimated)
Completion
Nov 2019 (estimated)
Last update
Feb 26, 2019

Study contacts

Yunling Zhang, PhD,MD
Contact
yunlingzhang2004@126.com
+86 10 6768963
Yunling Zhang, PhD,MD
Contact
yunlingzhang2004@126.com
+86 10 67689634
Yunling Zhang
study chair · Dongfang Hospital Beijing University of Chinese Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion